Drug Profile
Research programme: amyotrophic lateral sclerosis gene therapy - Gene Therapy Research Institution
Alternative Names: GT 0001 XLatest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Gene Therapy Research Institution
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in Japan (IV)
- 14 Sep 2018 Astellas Pharma and Gene Therapy Research Institution enter an option agreement for global development and commercial rights for GT 0001X for Amyotrophic lateral sclerosis
- 11 Aug 2017 Preclinical trials in Amyotrophic lateral sclerosis in Japan (IV) (Gene Therapy Research Institution pipeline, August 2017)